Sentences with phrase «pharma companies into»

That means transforming pharma companies into public goods producers

On Monday, United Therapeutics reached a deal to acquire Israel - based SteadyMed Therapeutics Inc. in a deal potentially valued at US$ 216mln, a move that eliminates a serious competitive threat to the Maryland biotech by literally pulling the speciality pharma company into its own corner.

Not exact matches

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

It's possible that Paulson and Vanguard decided to invest their gains into other pharma companies developing new drugs, but they are just as likely to put their money somewhere else.

Immuno - oncolocy has been the focus of Big Pharma and biotechs alike, with companies such as Merck (mrk), Bristol - Myers Squibb (bmy), Pfizer (pfe), Roche / Genentech, Juno (juno), Kite Pharma (kite), Novartis (nvs), and countless others pouring massive investments into the space (the Loncar ETF contains almost all of these companies).

A 2017 investigation into lobbying efforts by «Big Pharma» conducted by The Washington Post and 60 Minutes found that the companies spent more than $ 106 million to lobby Congress in an effort to pass more favorable drug laws.

Recognizing a growing niche for outsourcing services, McElroy launched The Research Network, which today gathers several dozen former pharma employees into a firm that helps companies work with contract research organizations.

The immediate payoff was a commercialization deal in age - related macular degeneration in which Pfizer became the first big pharma company to make a move into the use of embryonic stem cells as the basis for a tissue regeneration therapy.

Once academic and small company researchers make discoveries, pharma executives can contribute their scientific expertise to help turn those discovery into products.

Some of the diagnostics companies, for instance, are expanding, and there's been an influx of big pharma into the area recently.»

Another area that big pharma has traditionally been reluctant to get involved with is research into orphan diseases — ones that affect so few people that working on them is not usually considered commercially viable by large companies.

Fixing the market failure in antibiotics production means transforming pharma companies — or parts of them — into public goods producers, with public interest rather than profit driving R&D and marketing.

Pharma companies would favor investigations into drugs» effects, he said, but asked that drug producers and other stakeholders be included in decision - making.

Protein - based drugs are big business, yet biotech and pharma companies often struggle to turn proteins into medicines.

PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube ®, NeuroCube ®, and PhenoCube ® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.

So with the understanding that I sure as hell know what pervasive influence peddling can do to the process of peer review — because the pharma companies do actively recruit their «key opinion leaders» on the basis of things like editorial clout and that prominence within their specialty which gives them to hold responsibilities in peer review for «high impact» medical journals — you might appreciate why, when I got to read those e-mails in the FOI2009.zip archive last November, my immediate desire was for something brutally Sicilian to happen immediately and with spatter marks on the surrounding walls to the C.R.U. correspondents who had been concerting to infest and pervert the peer review process throughout the physical sciences wherever anything critical of the AGW hypothesis might be brought into publication.

Similarly, biomedical and pharmaceutical research is bedazzled by molecular genetics, has sequenced the genome of one or two humans and a handful of other species and invested trillions on very rigidly reductionistic bottom - up research into medicines and diseases — with the result of empty drug pipelines for the big pharma companies in spite of all this investment.

Salmon replaces interim COO Chris West who stepped into the role following the departure of Tim Wilcock last year to US company AAI Pharma.

It also assisted Fairstone Group, the UK's largest chartered financial planning firm, with a # 25m investment from Synova Capital (which was among the largest private equity investments in the region in 2016), and handled a # 15m fundraising for Quantum Pharma, a notable public company transaction that involved tapping into new and existing institutional investors for an accelerated book - build.

A lot of commenters have been expecting that challenge to turn into more money spent by pharma companies on biotech; but the Abbott - Piramal transaction emphasized that there's more than one way... [more]

Pharma companies want to introduce new innovative products, and their largest consumer is the government, especially when it is about inclusion into the social reimbursement system.

Galenica Group recently announced that it has entered into a definitive agreement to acquire the US company Relypsa, Inc., (NASDAQ: RLYP), further strengthening its Business unit Vifor Pharma by gaining full global rights to the potassium binder Veltassa ® (patiromer) for oral suspension and...

This week, the FTC published a report that claims that these settlements result in substantial extra delay in getting generic products into the market; and the European Commission requested information on the deals from several major pharma companies.

Galenica Group recently announced that it has entered into a definitive agreement to acquire the US company Relypsa, Inc., (NASDAQ: RLYP), further strengthening its Business unit Vifor Pharma by gaining full global rights to the potassium binder Veltassa ® (patiromer) for oral suspension and enhancing its growing position as a global specialty pharmaceutical company.

But I saw it recently, and it's a little like watching a train wreck: this woman wrote a book called Big Pharma's Sexy Little Secret about how (and it's possible I've missed everything there is to see here...) pharmaceutical companies purposely hire «cheerleader» types so that they can use sex — or the idea of it, anyway — to manipulate doctors into buying more of their product.

Because drug therapies are part of the solution to solve these problems, there's going to be continued investment by the government and by biotech and pharma companies, through R&D, to solve these problems, and that translates into, and explains, the current high demand for lab space.